Journal of cosmetic dermatology · 2026
A Single-Center, Open-Label Study to Evaluate the Efficacy and Tolerability of Retinal Encapsulated in a Novel Biomimetic Exosome in the Treatment of Mild-To-Moderate Facial Photodamage.
СтатьяКлиническое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gold Michael H, Enright Kaitlyn M, Ablon Glynis, Barbarino Sheila, Chilukuri Suneel, Day Doris, Goldberg David J, Lain Ted, Shamban Ava, Schlesinger Todd
Аннотация
BACKGROUND: Numerous retinoid-based skincare products are available over-the-counter for photodamaged and photoaged skin, but are associated with objective (e.g., erythema, dryness, flaking, edema) and subjective (e.g., itching, tingling, stinging, burning) tolerability issues. A novel retinal formulation was developed using an engineered biomimetic vegan exosome as a delivery system. The formulation also contains proprietary and potent hyaluronic acid, as well as plant-based actives commonly used in traditional herbal medicines for their anti-inflammatory and antioxidant properties.
AIMS: Evaluate the efficacy and tolerability of this biomimetic exosome-encapsulated retinal product for treatment of mild-to-moderate facial photodamage.
PATIENTS/METHODS: Twenty females aged 35 to 65 years, with Fitzpatrick skin types I-VI, mild-to-moderate facial fine lines and wrinkles, and mild-to-moderate facial photodamage, were assessed at screening/baseline and weeks 2, 4, 8, and 12. Investigator- and participant-assessed evaluations were performed at each visit. The primary objective was to demonstrate a decrease in the appearance of fine lines and wrinkles, erythema, as well as a reduction of overall facial photodamage after a 12-week topical regimen. The secondary objective was to measure the frequency of adverse events throughout the study.
RESULTS: Statistically significant improvements in erythema, skin tone, skin texture, and lines/wrinkles were observed at all follow-up visits, compared to baseline. At weeks 8 and 12, all participants (100%) displayed improvements in facial aesthetics. Most participants (19/20; 95.00%) were satisfied with the product and would recommend it to others. No product-related adverse events were reported.
CONCLUSIONS: Daily use of this "hydrating retinal" improved signs of facial photodamage with none to mild signs of skin irritation.
AIMS: Evaluate the efficacy and tolerability of this biomimetic exosome-encapsulated retinal product for treatment of mild-to-moderate facial photodamage.
PATIENTS/METHODS: Twenty females aged 35 to 65 years, with Fitzpatrick skin types I-VI, mild-to-moderate facial fine lines and wrinkles, and mild-to-moderate facial photodamage, were assessed at screening/baseline and weeks 2, 4, 8, and 12. Investigator- and participant-assessed evaluations were performed at each visit. The primary objective was to demonstrate a decrease in the appearance of fine lines and wrinkles, erythema, as well as a reduction of overall facial photodamage after a 12-week topical regimen. The secondary objective was to measure the frequency of adverse events throughout the study.
RESULTS: Statistically significant improvements in erythema, skin tone, skin texture, and lines/wrinkles were observed at all follow-up visits, compared to baseline. At weeks 8 and 12, all participants (100%) displayed improvements in facial aesthetics. Most participants (19/20; 95.00%) were satisfied with the product and would recommend it to others. No product-related adverse events were reported.
CONCLUSIONS: Daily use of this "hydrating retinal" improved signs of facial photodamage with none to mild signs of skin irritation.